Table 3

Antitumoral effects of doxorubicin, Met-free diet, and ethionine on the growth of SCLC6, a human SCLC established in nude mice, and on the growth of SCLC6-Dox, derived from SCLC6 after treatment with doxorubicin, as detailed in “Materials and Methods”

TumorsDietTreatmentRTV at day 14 Mean ± SDTumor growth inhibition (%) Mean ± SDTumor doubling time (days) Mean ± SDSurvival prolongation (days) Mean ± SD (ratio)a
SCLC6Regular dietNone22 ± 36 ± 1
Regular dietDoxorubicinb21 ± 41 ± 36 ± 0.80
MetHcy+cEthionined16 ± 228 ± 16e6 ± 0.72
MetHcy+Doxorubicin+ ethionine10 ± 1f51 ± 13f8 ± 28 (1.7)
SCLC6-DoxRegular dietNone25 ± 64 ± 0.60
Regular dietDoxorubicinb25 ± 304 ± 0.50
MetHcy+Ethionined23 ± 84 ± 24 ± 20
MetHcy+Doxorubicin+ ethionine7 ± 3f74 ± 12f8 ± 18 (1.7)
  • a Ratio to the survival time of untreated mice.

  • b Doxorubicin was injected i.p. 2 h after ethionine injection at a dose of 5 mg/kg, weekly.

  • c Mice were fed a MetHcy+ diet as soon as the tumors reached 60–100 mm3.

  • d Ethionine was injected i.p. daily, at a dose of 200 mg/kg.

  • e 0.05 < P < 0.01.

  • f P < 0.01.